viernes, 11 de marzo de 2011

Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies

¡Ojo, que Kaletra también se comercializa en España!


ISSUE: FDA notified healthcare professionals of serious health problems that have been reported in premature babies receiving Kaletra (lopinavir/ritonavir) oral solution. Kaletra oral solution contains the ingredients alcohol and propylene glycol. Premature babies may be at increased risk for health problems because they have a decreased ability to eliminate propylene glycol; this could lead to adverse events such as serious heart, kidney, or breathing problems. Because the consequences of using Kaletra oral solution in babies immediately after birth can be severe or possibly fatal, the label is being revised to include a new warning.

BACKGROUND: Kaletra oral solution is an antiviral medication used in combination with other antiretroviral drugs for the treatment of HIV-1 infection in pediatric patients 14 days of age (whether premature or full term) or older and in adults.

RECOMMENDATION: The use of Kaletra oral solution should be avoided in premature babies until 14 days after their due date, or in full-term babies younger than 14 days of age unless a healthcare professional believes that the benefit of using Kaletra oral solution to treat HIV infection immediately after birth outweighs the potential risks. In such cases, FDA strongly recommends monitoring for increases in serum osmolality, serum creatinine, and other signs of toxicity.

Healthcare professionals and patients are encouraged to report adverse events, side effects, or product quality problems related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event

Reporting Program:

•Complete and submit the report Online: www.fda.gov/MedWatch/report.htm

miércoles, 9 de marzo de 2011

Más del 37% de los efectos adversos en un hospital está relacionado con la medicación.

Noticia publicada en: http://www.noticiasmedicas.es/medicina/noticias/7335/1/Mas-del-37-de-los-efectos-adversos-en-un-hospital-esta-relacionado-con-la-medicacion-/Page1.html

- Un informe del Ministerio de Sanidad alerta sobre la seguridad de los pacientes en la asistencia hospitalaria. El 8,4% de los pacientes tiene efectos adversos y más del 42% son evitables


- El estudio señala que en 2006 murieron más de 12.600 pacientes por efectos adversos. Ese mismo año se registraron 4.129 muertos por accidente en las carreteras

- Profesionales sanitarios del Hospital Cruz Roja de Bilbao implantan un sistema pionero para garantizar la seguridad hospitalaria y minimizar los efectos adversos

- Esta tecnología asegura todos los procesos hospitalarios: transfusiones, operaciones quirúrgicas, trazabilidad de materiales, identificación de muestras analíticas o medicación